Revolutionizing Cancer Treatment: Oncotelic’s OT101 Shows Promising Results Against Pancreatic Cancer at SITC’s 37th Annual Meeting
Oncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meeting AGOURA HILLS, Calif., Sept. 28, 2022 (GLOBE NEWSWIRE) – Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a developer of treatments for rare and orphan indications, has announced that the Company will be presenting at the upcoming SITC 37th Annual…